1. Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
- Author
-
Georg F. Weber, Denis I. Trufa, Marcel Vetter, Thorsten Brenner, Torsten Birkholz, Andreas Hecker, Izabela Swierzy, Maximilian Brunner, Horia Sirbu, Ixchel Castellanos, Christian Krautz, Robert Grützmann, Kai Hildner, Andreas E. Kremer, Alan Bénard, Elisabeth Naschberger, Georg Schett, Enrico Richter, Fabian Edinger, Matthias Tenbusch, Marc M. Berger, Filip K. Swirski, Anne Jacobsen, Bettina Klösch, Hendrik Streeck, and Markus A. Weigand
- Subjects
Predictive marker ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,Medicine ,Secretion ,Interleukin-3 receptor ,Disease ,business ,Interleukin 3 - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. Here, we report that low plasma interleukin-3 (IL-3) levels were associated with increased severity and mortality during SARS-CoV-2 infections. IL-3 promoted the recruitment of antiviral circulating plasmacytoid dendritic cells (pDCs) into the airways by stimulating CXCL12 secretion from pulmonary CD123+epithelial cells. This study identifies IL-3 as a predictive disease marker and potential therapeutic target for SARS-CoV-2 infections.
- Published
- 2020
- Full Text
- View/download PDF